CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 13 enrolled
Drug / intervention
teriparatidedrug
Likely dose
teriparatide 20 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01705587
NCT01705587Phase 4Completed
CompareCT.gov

Fracture (FX) Improvement With Teriparatide: FiX-IT Study

Susan L. Greenspan·interventional·Posted Oct 12, 2012·Updated Dec 12, 2017

In Brief

A Phase 4 clinical trial evaluating teriparatide for Osteoporosis and Atypical Femoral Fracture. Completed, enrolled 13 participants across 1 site.

Detailed Summary

This open label comparison study examines the hypothesis that teriparatide given immediately following repair of an atypical subtrochanteric or diaphyseal femoral shaft fracture will enhance healing and improve bone mineral density compared to delayed treatment (after six months) with teriparatide or no treatment with teriparatide (patients who refuse therapy or for whom teriparatide is contraindicated). Patients with up-front teriparatide in addition will have greater quality of life measures and less pain compared to those with delayed or no therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Atypical Femoral Fracture
CountriesUnited States
CollaboratorsUniversity of Pittsburgh, Eli Lilly and Company

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 12, 2012
Enrollment StartDec 1, 2012
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.7 years ago

Interventions

teriparatidedrug

20 microgram once-daily subcutaneous injection